OTCMKTS:PPCB

Propanc Biopharma Stock Forecast, Price & News

$0.07
-0.02 (-22.22 %)
(As of 06/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.07
▼
$0.10
50-Day Range
$0.06
▼
$0.24
52-Week Range
$0.05
▼
$7.40
Volume608,519 shs
Average Volume218,525 shs
Market Capitalization$545,510.00
P/E RatioN/A
Dividend YieldN/A
Beta0.74
30 days | 90 days | 365 days | Advanced Chart
Receive PPCB News and Ratings via Email

Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Propanc Biopharma logo

About Propanc Biopharma

Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.

Headlines

Propanc Biopharma, Inc. (OTCMKTS:PPCB) Short Interest Up 4,783.3% in May
Propanc Biopharma, Inc. (OTCMKTS:PPCB) Short Interest Up 4,783.3% in May
June 11, 2021 |  americanbankingnews.com
Propanc Biopharma (OTCMKTS:PPCB) vs. Takeda Pharmaceutical (OTCMKTS:TKPYY) Head-To-Head Contrast
Propanc Biopharma (OTCMKTS:PPCB) vs. Takeda Pharmaceutical (OTCMKTS:TKPYY) Head-To-Head Contrast
June 7, 2021 |  americanbankingnews.com
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes
May 17, 2021 |  finance.yahoo.com
Propanc Biopharma Provides Upcoming Milestones
Propanc Biopharma Provides Upcoming Milestones
March 25, 2021 |  finance.yahoo.com
Propanc Biopharma Provides A Shareholder Update for 2021
Propanc Biopharma Provides A Shareholder Update for 2021
March 3, 2021 |  finance.yahoo.com
Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients
Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients
February 15, 2021 |  finance.yahoo.com
Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment
Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment
January 28, 2021 |  finance.yahoo.com
Propanc Biopharma, Inc.: Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
Propanc Biopharma, Inc.: Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
January 19, 2021 |  finanznachrichten.de
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
January 19, 2021 |  finance.yahoo.com
Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers
Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers
January 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.66 out of 5 stars

Medical Sector

1358th out of 2,105 stocks

Pharmaceutical Preparations Industry

610th out of 832 stocks

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Propanc Biopharma (OTCMKTS:PPCB) Frequently Asked Questions

What stocks does MarketBeat like better than Propanc Biopharma?

Wall Street analysts have given Propanc Biopharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Propanc Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Propanc Biopharma?

Propanc Biopharma saw a increase in short interest in May. As of May 28th, there was short interest totaling 58,600 shares, an increase of 4,783.3% from the May 13th total of 1,200 shares. Based on an average daily volume of 431,400 shares, the short-interest ratio is presently 0.1 days.
View Propanc Biopharma's Short Interest.

When is Propanc Biopharma's next earnings date?

Propanc Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, October 7th 2021.
View our earnings forecast for Propanc Biopharma.

How has Propanc Biopharma's stock been impacted by Coronavirus (COVID-19)?

Propanc Biopharma's stock was trading at $0.0449 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PPCB stock has increased by 55.9% and is now trading at $0.07.
View which stocks have been most impacted by COVID-19.

Who are Propanc Biopharma's key executives?

Propanc Biopharma's management team includes the following people:
  • Mr. James Nathanielsz, Exec. Chairman, CEO, CFO, Treasurer & Sec. (Age 47, Pay $590.19k)
  • Dr. Julian Norman Kenyon, Chief Scientific Officer & Director (Age 73, Pay $27.3k)
  • Prof. Klaus Kutz, Acting Chief Medical Officer & Member of Scientific Advisory Board

Who are some of Propanc Biopharma's key competitors?

Some companies that are related to Propanc Biopharma include VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUC), Melinta Therapeutics (MLNTQ), Adhera Therapeutics (ATRX), Cotinga Pharmaceuticals (COTQF), Aoxing Pharmaceutical (AOXG), W World (WWHC), Earth Science Tech (ETST), Cardax (CDXI), Anthera Pharmaceuticals (ANTH), Aeolus Pharmaceuticals (AOLS), TetraLogic Pharmaceuticals (TLOG), Sophiris Bio (SPHS), Sienna Biopharmaceuticals (SNNAQ) and Argos Therapeutics (ARGSQ).
View all of PPCB's competitors.

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Avis Budget Group (CAR), (CGC), Cronos Group (CRON), CRISPR Therapeutics (CRSP), Petroteq Energy (PQEFF), Xerox (XRX), Aurora Cannabis (ACBFF), Amgen (AMGN), Amarin (AMRN) and Aphria (APHQF).

What is Propanc Biopharma's stock symbol?

Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB."

How do I buy shares of Propanc Biopharma?

Shares of PPCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Propanc Biopharma's stock price today?

One share of PPCB stock can currently be purchased for approximately $0.07.

How much money does Propanc Biopharma make?

Propanc Biopharma has a market capitalization of $545,510.00.

How many employees does Propanc Biopharma have?

Propanc Biopharma employs 1 workers across the globe.

What is Propanc Biopharma's official website?

The official website for Propanc Biopharma is www.propanc.com.

Where are Propanc Biopharma's headquarters?

Propanc Biopharma is headquartered at 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124.

How can I contact Propanc Biopharma?

Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The company can be reached via phone at 610398820780 or via email at [email protected]


This page was last updated on 6/23/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.